Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Point of Care Infectious Disease Market by Method (Antibody Based Diagnosis, Microbial Particle Based Diagnosis) and by End Users (Hospitals, Emergency Rooms, Ambulatory Care Centres, Surgery Centres, Birth Centres): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03435

Pages: NA

Charts: NA

Tables: NA

Point of care or POC infectious disease market mainly consists of the POC tests done to detect infectious diseases present in an individual. The sole objective of the POC tests are to provide early diagnosis and hence an early treatment. These tests either employ antibodies or microbial particles to detect the infection.

The drivers that drive the market growth are the rise in the cases of infectious diseases, increase in the disposable income and rapid increase in medical tourism. However, lack of awareness about POC tests restraint the market growth. Technological developments in the field of POC tests will prove as future opportunities for the market growth.

The report segments the market on the basis of method, end users and region. Based on method, the market is segmented into antibody based diagnosis and microbial particle based diagnosis. Based on end users, the market has been segmented into hospitals, emergency rooms, ambulatory care centres, surgery centres, birth centres and others. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market are Diasorin S.p.A, F Hoffmann La Roche Ltd., SeraCare, ThermoFisher Scientific Inc., Hologi Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Becton, Dickenson and Company (BD), Alere and Enzo Biochem Inc.

Key Benefits

  • The study provides an in-depth analysis of the global point of care infectious disease market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry is provided for the to assiststakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps in understanding the trends in method, and end users of point of care infectious disease across the globe.
  • Key market players and their strategies have been provided to understand the competitive outlook of theindustry.

 Key Market Segments

  • By Method
    • Antibody Based Diagnosis
    • Microbial Particle Based Diagnosis
  • By End Users
    • Hospitals
    • Emergency Rooms
    • Ambulatory Care Centres
    • Surgery Centres
    • Birth Centres
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Turkey
      • Argentina
      • Rest of LAMEA

 
Key Market Players

  • Alere
  • Becton, Dickenson and Company (BD)
  • Enzo Biochem Inc.
  • ThermoFisher Scientific Inc.
  • Hologi Inc.
  • Bio-Rad Laboratories Inc.
  • Diasorin S.p.A
  • F Hoffmann La Roche Ltd.
  • Abbott Laboratories
  • SeraCare

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: POINT OF CARE INFECTIOUS DISEASE MARKET, BY METHOD

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Method

    • 4.2. Antibody Based Diagnosis

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Microbial Particle Based Diagnosis

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End Users

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Emergency Rooms

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Ambulatory Care Centres

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Surgery Centres

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Birth Centres

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: POINT OF CARE INFECTIOUS DISEASE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Method

      • 6.2.3. Market Size and Forecast, By End Users

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Point Of Care Infectious Disease Market

        • 6.2.5.1. Market Size and Forecast, By Method
        • 6.2.5.2. Market Size and Forecast, By End Users

      • 6.2.6. Canada Point Of Care Infectious Disease Market

        • 6.2.6.1. Market Size and Forecast, By Method
        • 6.2.6.2. Market Size and Forecast, By End Users

      • 6.2.7. Mexico Point Of Care Infectious Disease Market

        • 6.2.7.1. Market Size and Forecast, By Method
        • 6.2.7.2. Market Size and Forecast, By End Users

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Method

      • 6.3.3. Market Size and Forecast, By End Users

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Point Of Care Infectious Disease Market

        • 6.3.5.1. Market Size and Forecast, By Method
        • 6.3.5.2. Market Size and Forecast, By End Users

      • 6.3.6. Germany Point Of Care Infectious Disease Market

        • 6.3.6.1. Market Size and Forecast, By Method
        • 6.3.6.2. Market Size and Forecast, By End Users

      • 6.3.7. Italy Point Of Care Infectious Disease Market

        • 6.3.7.1. Market Size and Forecast, By Method
        • 6.3.7.2. Market Size and Forecast, By End Users

      • 6.3.8. Spain Point Of Care Infectious Disease Market

        • 6.3.8.1. Market Size and Forecast, By Method
        • 6.3.8.2. Market Size and Forecast, By End Users

      • 6.3.9. UK Point Of Care Infectious Disease Market

        • 6.3.9.1. Market Size and Forecast, By Method
        • 6.3.9.2. Market Size and Forecast, By End Users

      • 6.3.10. Russia Point Of Care Infectious Disease Market

        • 6.3.10.1. Market Size and Forecast, By Method
        • 6.3.10.2. Market Size and Forecast, By End Users

      • 6.3.11. Rest Of Europe Point Of Care Infectious Disease Market

        • 6.3.11.1. Market Size and Forecast, By Method
        • 6.3.11.2. Market Size and Forecast, By End Users

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Method

      • 6.4.3. Market Size and Forecast, By End Users

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Point Of Care Infectious Disease Market

        • 6.4.5.1. Market Size and Forecast, By Method
        • 6.4.5.2. Market Size and Forecast, By End Users

      • 6.4.6. Japan Point Of Care Infectious Disease Market

        • 6.4.6.1. Market Size and Forecast, By Method
        • 6.4.6.2. Market Size and Forecast, By End Users

      • 6.4.7. India Point Of Care Infectious Disease Market

        • 6.4.7.1. Market Size and Forecast, By Method
        • 6.4.7.2. Market Size and Forecast, By End Users

      • 6.4.8. South Korea Point Of Care Infectious Disease Market

        • 6.4.8.1. Market Size and Forecast, By Method
        • 6.4.8.2. Market Size and Forecast, By End Users

      • 6.4.9. Australia Point Of Care Infectious Disease Market

        • 6.4.9.1. Market Size and Forecast, By Method
        • 6.4.9.2. Market Size and Forecast, By End Users

      • 6.4.10. Thailand Point Of Care Infectious Disease Market

        • 6.4.10.1. Market Size and Forecast, By Method
        • 6.4.10.2. Market Size and Forecast, By End Users

      • 6.4.11. Malaysia Point Of Care Infectious Disease Market

        • 6.4.11.1. Market Size and Forecast, By Method
        • 6.4.11.2. Market Size and Forecast, By End Users

      • 6.4.12. Indonesia Point Of Care Infectious Disease Market

        • 6.4.12.1. Market Size and Forecast, By Method
        • 6.4.12.2. Market Size and Forecast, By End Users

      • 6.4.13. Rest of Asia Pacific Point Of Care Infectious Disease Market

        • 6.4.13.1. Market Size and Forecast, By Method
        • 6.4.13.2. Market Size and Forecast, By End Users

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Method

      • 6.5.3. Market Size and Forecast, By End Users

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Point Of Care Infectious Disease Market

        • 6.5.5.1. Market Size and Forecast, By Method
        • 6.5.5.2. Market Size and Forecast, By End Users

      • 6.5.6. South Africa Point Of Care Infectious Disease Market

        • 6.5.6.1. Market Size and Forecast, By Method
        • 6.5.6.2. Market Size and Forecast, By End Users

      • 6.5.7. Saudi Arabia Point Of Care Infectious Disease Market

        • 6.5.7.1. Market Size and Forecast, By Method
        • 6.5.7.2. Market Size and Forecast, By End Users

      • 6.5.8. UAE Point Of Care Infectious Disease Market

        • 6.5.8.1. Market Size and Forecast, By Method
        • 6.5.8.2. Market Size and Forecast, By End Users

      • 6.5.9. Argentina Point Of Care Infectious Disease Market

        • 6.5.9.1. Market Size and Forecast, By Method
        • 6.5.9.2. Market Size and Forecast, By End Users

      • 6.5.10. Rest of LAMEA Point Of Care Infectious Disease Market

        • 6.5.10.1. Market Size and Forecast, By Method
        • 6.5.10.2. Market Size and Forecast, By End Users

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Diasorin S.p.A

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. F Hoffmann La Roche Ltd.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. SeraCare

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. ThermoFisher Scientific Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Hologi Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Abbott Laboratories

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Bio-Rad Laboratories Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Becton, Dickenson And Company (BD)

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Alere

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Enzo Biochem Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR ANTIBODY BASED DIAGNOSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR MICROBIAL PARTICLE BASED DIAGNOSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR EMERGENCY ROOMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR AMBULATORY CARE CENTRES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR SURGERY CENTRES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET FOR BIRTH CENTRES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA POINT OF CARE INFECTIOUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 14. U.S. POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 15. U.S. POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 16. CANADA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 17. CANADA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE POINT OF CARE INFECTIOUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 27. ITALY POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 28. ITALY POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 31. UK POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 32. UK POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC POINT OF CARE INFECTIOUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 40. CHINA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 41. CHINA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 44. INDIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 45. INDIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA POINT OF CARE INFECTIOUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 67. UAE POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 68. UAE POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA POINT OF CARE INFECTIOUS DISEASE, BY METHOD, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA POINT OF CARE INFECTIOUS DISEASE, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 73. DIASORIN S.P.A: KEY EXECUTIVES
  • TABLE 74. DIASORIN S.P.A: COMPANY SNAPSHOT
  • TABLE 75. DIASORIN S.P.A: OPERATING SEGMENTS
  • TABLE 76. DIASORIN S.P.A: PRODUCT PORTFOLIO
  • TABLE 77. DIASORIN S.P.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. F HOFFMANN LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 79. F HOFFMANN LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 80. F HOFFMANN LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 81. F HOFFMANN LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 82. F HOFFMANN LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. SERACARE: KEY EXECUTIVES
  • TABLE 84. SERACARE: COMPANY SNAPSHOT
  • TABLE 85. SERACARE: OPERATING SEGMENTS
  • TABLE 86. SERACARE: PRODUCT PORTFOLIO
  • TABLE 87. SERACARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. THERMOFISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 89. THERMOFISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 90. THERMOFISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 91. THERMOFISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 92. THERMOFISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. HOLOGI INC.: KEY EXECUTIVES
  • TABLE 94. HOLOGI INC.: COMPANY SNAPSHOT
  • TABLE 95. HOLOGI INC.: OPERATING SEGMENTS
  • TABLE 96. HOLOGI INC.: PRODUCT PORTFOLIO
  • TABLE 97. HOLOGI INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 99. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 100. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 101. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 102. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. BIO-RAD LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 104. BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 105. BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 106. BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 107. BIO-RAD LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. BECTON, DICKENSON AND COMPANY (BD): KEY EXECUTIVES
  • TABLE 109. BECTON, DICKENSON AND COMPANY (BD): COMPANY SNAPSHOT
  • TABLE 110. BECTON, DICKENSON AND COMPANY (BD): OPERATING SEGMENTS
  • TABLE 111. BECTON, DICKENSON AND COMPANY (BD): PRODUCT PORTFOLIO
  • TABLE 112. BECTON, DICKENSON AND COMPANY (BD): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. ALERE: KEY EXECUTIVES
  • TABLE 114. ALERE: COMPANY SNAPSHOT
  • TABLE 115. ALERE: OPERATING SEGMENTS
  • TABLE 116. ALERE: PRODUCT PORTFOLIO
  • TABLE 117. ALERE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ENZO BIOCHEM INC.: KEY EXECUTIVES
  • TABLE 119. ENZO BIOCHEM INC.: COMPANY SNAPSHOT
  • TABLE 120. ENZO BIOCHEM INC.: OPERATING SEGMENTS
  • TABLE 121. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO
  • TABLE 122. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL POINT OF CARE INFECTIOUS DISEASE MARKET
  • FIGURE 3. SEGMENTATION POINT OF CARE INFECTIOUS DISEASE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN POINT OF CARE INFECTIOUS DISEASE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPOINT OF CARE INFECTIOUS DISEASE MARKET
  • FIGURE 11. POINT OF CARE INFECTIOUS DISEASE MARKET SEGMENTATION, BY BY METHOD
  • FIGURE 12. POINT OF CARE INFECTIOUS DISEASE MARKET FOR ANTIBODY BASED DIAGNOSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. POINT OF CARE INFECTIOUS DISEASE MARKET FOR MICROBIAL PARTICLE BASED DIAGNOSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. POINT OF CARE INFECTIOUS DISEASE MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 15. POINT OF CARE INFECTIOUS DISEASE MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. POINT OF CARE INFECTIOUS DISEASE MARKET FOR EMERGENCY ROOMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. POINT OF CARE INFECTIOUS DISEASE MARKET FOR AMBULATORY CARE CENTRES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. POINT OF CARE INFECTIOUS DISEASE MARKET FOR SURGERY CENTRES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. POINT OF CARE INFECTIOUS DISEASE MARKET FOR BIRTH CENTRES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: POINT OF CARE INFECTIOUS DISEASE MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. DIASORIN S.P.A: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. DIASORIN S.P.A: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. DIASORIN S.P.A: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. F HOFFMANN LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. F HOFFMANN LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. F HOFFMANN LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. SERACARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. SERACARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. SERACARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. THERMOFISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. THERMOFISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. THERMOFISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. HOLOGI INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. HOLOGI INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. HOLOGI INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. BIO-RAD LABORATORIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. BIO-RAD LABORATORIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. BIO-RAD LABORATORIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. BECTON, DICKENSON AND COMPANY (BD): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. BECTON, DICKENSON AND COMPANY (BD): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. BECTON, DICKENSON AND COMPANY (BD): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ALERE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ALERE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ALERE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. ENZO BIOCHEM INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. ENZO BIOCHEM INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. ENZO BIOCHEM INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Point of Care Infectious Disease Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved